Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Superoxide dismutase analogue - LTT Bio-Pharma

Drug Profile

Superoxide dismutase analogue - LTT Bio-Pharma

Alternative Names: Lecithin-modified superoxide dismutase - LTT Bio-Pharma; LT-0011; LT-1001 - LTT Bio-Pharma; LT-1002; PC-SOD; PC-SOD NE; Recombinant midismase - LTT Bio-Pharma

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LTT Bio-Pharma
  • Developer Beijing Tide Pharmaceutical; Chong Kun Dang; LTT Bio-Pharma
  • Class Anti-inflammatories; Anti-ischaemics; Oxidoreductases
  • Mechanism of Action Antioxidants; Superoxide dismutase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Interstitial lung diseases; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Peripheral neuropathies; Reperfusion injury; Stroke; Ulcerative colitis
  • Phase I Adult respiratory distress syndrome
  • No development reported Acute kidney injury; Chronic obstructive pulmonary disease; Interstitial lung diseases; Myocardial reperfusion injury

Most Recent Events

  • 05 Apr 2024 Phase-I development is ongoing for Adult respiratory distress syndrome in Japan (IV, Injection) (LTT Bio-Pharma pipeline, April 2024)
  • 05 Apr 2024 Phase-II development is ongoing for Stroke (IV, Injection) (LTT Bio-Pharma pipeline, April 2024)
  • 05 Apr 2024 Phase-II development is ongoing for Ulcerative colitis (IV, Injection) (LTT Bio-Pharma pipeline, April 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top